Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints
Publication
, Journal Article
Melton, J; Harrelson-Woodlief, L; Cohen, H; Hlatky, M; Lipscomb, J; Califf, R; Mark, D
Published in: Controlled Clinical Trials
January 1, 1990
Duke Scholars
Published In
Controlled Clinical Trials
DOI
ISSN
0197-2456
Publication Date
January 1, 1990
Volume
11
Issue
4
Start / End Page
268
Related Subject Headings
- Public Health
- General Clinical Medicine
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Melton, J., Harrelson-Woodlief, L., Cohen, H., Hlatky, M., Lipscomb, J., Califf, R., & Mark, D. (1990). Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints. Controlled Clinical Trials, 11(4), 268. https://doi.org/10.1016/0197-2456(90)90077-F
Melton, J., L. Harrelson-Woodlief, H. Cohen, M. Hlatky, J. Lipscomb, R. Califf, and D. Mark. “Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints.” Controlled Clinical Trials 11, no. 4 (January 1, 1990): 268. https://doi.org/10.1016/0197-2456(90)90077-F.
Melton J, Harrelson-Woodlief L, Cohen H, Hlatky M, Lipscomb J, Califf R, et al. Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints. Controlled Clinical Trials. 1990 Jan 1;11(4):268.
Melton, J., et al. “Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints.” Controlled Clinical Trials, vol. 11, no. 4, Jan. 1990, p. 268. Scopus, doi:10.1016/0197-2456(90)90077-F.
Melton J, Harrelson-Woodlief L, Cohen H, Hlatky M, Lipscomb J, Califf R, Mark D. Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints. Controlled Clinical Trials. 1990 Jan 1;11(4):268.
Published In
Controlled Clinical Trials
DOI
ISSN
0197-2456
Publication Date
January 1, 1990
Volume
11
Issue
4
Start / End Page
268
Related Subject Headings
- Public Health
- General Clinical Medicine
- 11 Medical and Health Sciences